Earnings ·
Armata Pharmaceuticals reported a net income of $74.1 million for Q2 2026, driven by a $91.0 million non-cash gain…
ARMPArmata Pharmaceuticals, Inc.
Armata Pharmaceuticals reported a net income of $74.1 million for Q2 2026, driven by a $91.0 million non-cash gain from the change in fair value of its Convertible Loan. The company recognized $2.5 million in grant revenue and incurred $12.8 million in operating expenses. Cash balances rose to $24.0 million following a $25.0 million term loan, $2.4 million in ATM proceeds, and $1.2 million from option exercises. Clinically, Armata submitted its Phase 3 protocol for AP-SA02 to the FDA, received Fast Track designation, and secured an Agreed Initial Pediatric Study Plan. The company also announced the promotion of David House to Chief Financial Officer and the appointment of Daniel B. Gilmer to its Board of Directors. Armata Pharmaceuticals is a late clinical-stage biotechnology company focused on developing bacteriophage therapeutics for antibiotic-resistant bacterial infections.